HC Wainwright Boosts Earnings Estimates for Alpha Cognition

Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) - Equities researchers at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for Alpha Cognition in a research report issued on Monday, March 31st. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.38) for the quarter, up from their prior forecast of ($0.72). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock.

Separately, Raymond James upgraded shares of Alpha Cognition to a "moderate buy" rating in a research note on Tuesday, March 25th.

Alpha Cognition Stock Performance

Shares of ACOG traded up $0.24 during midday trading on Thursday, reaching $4.67. The stock had a trading volume of 46,076 shares, compared to its average volume of 75,590. The stock has a market cap of $74.81 million, a price-to-earnings ratio of -1.82 and a beta of 2.50. The company's 50 day simple moving average is $5.69. Alpha Cognition has a one year low of $4.28 and a one year high of $7.00.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last released its earnings results on Monday, March 31st. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.03).

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Sphera Funds Management LTD. bought a new position in Alpha Cognition during the fourth quarter worth $3,652,000. Bleichroeder LP acquired a new stake in shares of Alpha Cognition during the 4th quarter worth about $1,024,000. Alyeska Investment Group L.P. bought a new stake in shares of Alpha Cognition during the 4th quarter worth about $2,356,000. Manatuck Hill Partners LLC acquired a new position in Alpha Cognition in the 4th quarter valued at about $395,000. Finally, Tudor Investment Corp ET AL bought a new position in Alpha Cognition in the 4th quarter valued at about $412,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.